Drugs Containing Excipient (Inactive Ingredient) OCTENYLSUCCINIC ACID

« Back to Dashboard

Generic drugs containing OCTENYLSUCCINIC ACID excipient

Company	Ingredient	NDC	Excipient
Ajanta Pharma USA Inc	valganciclovir hydrochloride	27241-159	OCTENYLSUCCINIC ACID

Octenylsuccinic Acid Pharmaceutical Excipient Market: Dynamics, Applications, Suppliers, and Financial Trajectory

Last updated: August 28, 2026

Octenylsuccinic acid is not a major standalone pharmaceutical excipient market. Commercial activity centers on octenyl succinic anhydride, or OSA, and OSA-modified starches such as sodium starch octenyl succinate. Pharmaceutical demand is driven by specialty formulations, including oral emulsions, spray-dried powders, taste-masked products, and lipid-based delivery systems. Public company filings do not report OSA pharmaceutical revenue separately, so market size and supplier profitability cannot be stated with precision. The most defensible outlook is for low-to-moderate volume growth with higher value per kilogram in regulated pharmaceutical grades.

What is octenylsuccinic acid and how is it used in pharmaceuticals?

Octenylsuccinic acid is a hydrophobic, amphiphilic succinic-acid derivative. In commercial excipient production, the more relevant intermediate is usually octenyl succinic anhydride, which reacts with starch to produce OSA-modified starches.

The pharmaceutical value chain is:

Stage	Material	Principal function
Chemical intermediate	Octenyl succinic anhydride	Reagent for starch modification
Modified excipient	Sodium starch octenyl succinate	Emulsification, encapsulation, powder formation
Formulation system	OSA-modified starch blends	Oral delivery, taste masking, lipid and poorly soluble drug delivery

OSA-modified starch contains both hydrophilic starch segments and hydrophobic octenyl groups. That structure allows it to stabilize oil-in-water systems, improve powder dispersibility, and assist in the encapsulation of lipophilic active pharmaceutical ingredients.

Common pharmaceutical applications include:

• Oral emulsions and suspensions
• Spray-dried drug powders
• Taste masking for bitter active ingredients
• Lipid-based delivery systems
• Amorphous solid dispersions
• Nutraceutical and pharmaceutical soft-gel systems
• Dry formulations containing oils, vitamins, or volatile ingredients

The material is more important as a functional delivery excipient than as a chemically active ingredient.

How large is the octenylsuccinic acid pharmaceutical excipient market?

No authoritative public source reports a standalone global market size for octenylsuccinic acid used in pharmaceuticals. Commercial market reports generally combine OSA-modified starch with food emulsifiers, encapsulation materials, modified starches, or broader pharmaceutical excipients.

The market should therefore be assessed through demand indicators rather than a single headline figure.

Market indicator	Direction	Commercial implication
Pharmaceutical use of OSA-modified starch	Growing from a small base	Supports specialty-grade demand
Food and beverage use	Larger than pharmaceutical use	Provides supplier scale and manufacturing utilization
Nutraceutical use	Growing	Expands demand for encapsulation and powder technologies
Direct use of free octenylsuccinic acid	Limited	Lowers the addressable pharmaceutical volume
Demand for spray-drying excipients	Positive	Supports OSA-modified starch adoption
Demand for poorly soluble drug technologies	Positive	Creates formulation opportunities
Commodity starch pricing	Cyclical	Can compress margins
Regulatory documentation requirements	Increasing	Favors established suppliers

The pharmaceutical segment is likely a small fraction of the broader OSA-modified starch market. Supplier economics depend on serving food, beverage, nutrition, cosmetics, and pharmaceutical customers from the same production platform.

What are the main pharmaceutical applications for OSA-modified starch?

Oral emulsions and suspensions

OSA-modified starch can stabilize oil droplets and improve the physical stability of oral liquid formulations. This is relevant to products containing fat-soluble vitamins, essential oils, cannabinoids, and poorly water-soluble drug substances.

The commercial advantage is formulation flexibility. OSA-modified starch may reduce reliance on synthetic surfactants or allow a more favorable sensory profile in oral products.

Spray-dried powders

OSA-modified starch is used as a carrier and encapsulation matrix in spray drying. It can improve powder recovery, protect sensitive ingredients, and support redispersion after processing.

Applications include:

• Lipophilic drug substances
• Volatile compounds
• Vitamins
• Botanical actives
• Combination powders for oral reconstitution

Pharmaceutical-grade spray-drying applications can command higher prices than food-grade material because of batch documentation, microbial controls, traceability, and change-control requirements.

Taste masking

Hydrophobic modification can help entrap or coat bitter compounds. The excipient may be incorporated into microparticles, dry powders, or reconstitutable suspensions.

The principal commercial constraint is that taste masking must be balanced against drug release. Excessive hydrophobicity can delay dissolution or create content-uniformity problems.

Amorphous solid dispersions

OSA-modified starch may be evaluated as a carrier for poorly soluble compounds. Its utility depends on the drug’s chemistry, the required drug loading, glass-transition behavior, moisture sensitivity, and dissolution profile.

It competes with polymers such as hypromellose acetate succinate, copovidone, polyvinylpyrrolidone, and cellulose derivatives. OSA-modified starch is more likely to occupy a niche position than displace these established polymers across broad portfolios.

Which companies supply OSA-modified pharmaceutical excipients?

The commercial supply base is concentrated among modified-starch manufacturers and excipient specialists. The most visible participants include Ingredion and suppliers operating through branded starch and encapsulation portfolios.

Company or supplier group	Relevant capability	Strategic position
Ingredion	OSA-modified starches, encapsulation and formulation ingredients	Large-scale starch platform with food, nutrition, and pharmaceutical reach
Tate & Lyle	Modified starch and specialty carbohydrate systems	Broad excipient and formulation infrastructure
Roquette	Pharmaceutical excipients and carbohydrate-based delivery materials	Strong pharmaceutical documentation and global distribution
Agrana	Modified starches and specialty carbohydrate products	Regional and global starch supply
Cargill	Starch derivatives and encapsulation materials	Large feedstock and processing base
Specialty excipient distributors	Regional sourcing and regulatory support	Important for smaller pharmaceutical customers

Product branding and exact pharmaceutical grades vary by jurisdiction. A supplier may sell the same functional chemistry under separate food, nutrition, cosmetic, and pharmaceutical product names.

The supply market is less concentrated at the chemical-intermediate level than at the qualified pharmaceutical-excipient level. Pharmaceutical customers usually value documentation, consistency, and regulatory support more than the lowest raw-material price.

What determines the financial trajectory of the OSA excipient market?

The financial trajectory depends on five variables.

1. Pharmaceutical adoption remains application-led

OSA-modified starch is generally selected after formulation development identifies a specific need. It is not a default filler comparable to lactose, microcrystalline cellulose, or starch.

Revenue growth therefore depends on successful product development programs rather than broad substitution across standard dosage forms. Each new approval can generate recurring demand, but volumes may remain modest unless the product reaches a large patient population.

2. Food and nutrition volumes support manufacturing economics

Food and beverage applications, including beverage emulsions, flavor encapsulation, and clouding systems, are typically larger than pharmaceutical applications. Shared manufacturing allows suppliers to spread fixed costs across multiple markets.

This structure reduces pharmaceutical supply risk but also means that pharmaceutical demand alone may not justify a dedicated production asset.

3. Pharmaceutical grades produce better pricing but higher costs

Pharmaceutical grades can command a premium because they require:

• Tighter specification control
• Validated analytical methods
• Controlled microbial limits
• Traceability of raw materials
• Formal change notification
• Stability data
• Audit support
• Regulatory files and quality agreements

The net margin is not determined by price per kilogram alone. Quality-system costs, small batch sizes, testing, customer qualification, and inventory requirements can materially reduce contribution margins.

4. Starch and energy prices create input-cost volatility

The underlying cost base includes starch feedstocks, OSA chemical reagents, utilities, water treatment, drying, packaging, and quality control. Agricultural prices and energy costs can affect gross margin.

Suppliers with integrated starch operations are better positioned to manage feedstock volatility. Smaller toll manufacturers may face higher purchasing costs and less ability to pass through inflation.

5. New delivery technologies create upside

Growth opportunities are strongest where OSA-modified starch solves a technical problem:

• Poor aqueous solubility
• Unacceptable taste
• Low powder recovery
• Instability of oil-soluble actives
• Difficult redispersion
• Need for reduced synthetic surfactant content

The commercial upside is higher in complex formulations than in conventional immediate-release tablets.

How does OSA-modified starch compare with competing pharmaceutical excipients?

Excipient class	Main strength	Main limitation	Competitive position versus OSA-modified starch
Sodium starch glycolate	Tablet disintegration	Limited emulsification function	Stronger for tablets, weaker for lipid delivery
Hypromellose derivatives	Controlled release and dispersion	Higher processing and cost complexity	More established for solid dispersions
Maltodextrin	Low cost and spray-drying utility	Limited interfacial functionality	Cheaper but less effective as an emulsifier
Gum arabic	Encapsulation and emulsion stabilization	Supply and performance variability	Established alternative in encapsulation
Modified cellulose polymers	Broad pharmaceutical use	Can require organic solvents or complex processing	More mature regulatory position
Polysorbates	Strong emulsification	Oxidation and degradation concerns	More potent surfactants, different risk profile
OSA-modified starch	Emulsion stabilization and powder formation	Smaller pharmaceutical evidence base	Attractive for specialized oral delivery

OSA-modified starch is most competitive when the formulation needs both carbohydrate-based powder formation and interfacial stabilization. It is less competitive as a generic binder, filler, disintegrant, or tablet coating polymer.

What is the FDA regulatory status of OSA pharmaceutical excipients?

The regulatory status depends on the specific substance and intended use.

The U.S. Food and Drug Administration permits certain modified starches for food use under 21 C.F.R. § 172.892. That food regulation does not automatically establish approval for every pharmaceutical dosage form or every OSA-derived material.

For pharmaceuticals, the relevant pathway is usually excipient justification in a drug application. The sponsor must establish identity, specifications, manufacturing controls, safety, compatibility, and performance in the proposed formulation. The FDA Inactive Ingredient Database may support regulatory precedent when the exact substance, route, dosage form, and amount are covered, but the database is not a blanket approval for all uses (U.S. Food and Drug Administration, n.d.-a).

In Europe and other jurisdictions, sodium starch octenyl succinate is associated with food additive designation E1450. That status is relevant to safety history but does not replace pharmaceutical qualification. European pharmaceutical use still depends on the product dossier, pharmacopoeial position, supplier controls, and national regulatory expectations (European Commission, n.d.).

Does OSA have Orange Book-listed pharmaceutical patents?

No Orange Book listing attaches to octenylsuccinic acid as a standalone excipient. The Orange Book lists patents and exclusivity associated with approved drug products, not a general patent estate for an excipient chemistry (U.S. Food and Drug Administration, n.d.-b).

Patent protection may arise from:

• A drug formulation containing OSA-modified starch
• A spray-drying process
• A taste-masking composition
• A specific drug-excipient ratio
• A particle-size or substitution-degree range
• A manufacturing process
• A combination delivery system

These rights are product-specific. They do not create broad exclusivity over all pharmaceutical use of OSA-modified starch.

What patent and intellectual-property barriers affect OSA excipient suppliers?

The strongest intellectual-property barriers are usually process and formulation know-how rather than composition-of-matter claims over the basic OSA chemistry.

Key protectable areas include:

1. Degree of substitution and substitution distribution
2. Particle-size control
3. Moisture content and drying conditions
4. Spray-drying parameters
5. Encapsulation efficiency
6. Drug-loading levels
7. Stabilizer combinations
8. Taste-masking structures
9. Specific oral dosage forms
10. Manufacturing quality controls and scale-up methods

A supplier may hold patents covering a particular modified-starch preparation, but customers often rely on confidential manufacturing information as much as published patent claims. The practical barrier is qualification: changing suppliers can require comparative testing, stability work, regulatory amendments, and process validation.

The absence of a standalone Orange Book estate means generic-entry risk is usually assessed at the drug-product level. Paragraph IV disputes may involve an OSA-containing formulation, but the excipient itself is unlikely to be the central patent issue.

When does OSA lose exclusivity?

OSA itself has no single pharmaceutical exclusivity date. The core chemistry is old and broadly available. Exclusivity periods arise from individual drug products, formulation patents, process patents, trade secrets, supplier agreements, or regulatory protections.

Protection type	Typical relevance
Basic OSA chemistry	Generally mature and broadly accessible
Supplier process know-how	May remain commercially important without public expiration
Formulation patent	Expires according to the individual patent term
Drug-product patent	May affect generic or 505(b)(2) entry
Regulatory exclusivity	Belongs to the approved drug, not the excipient
Confidential quality package	Persists through contractual and operational controls

A competitor can often use another OSA-modified starch or an alternative excipient, subject to formulation performance and regulatory requirements. The commercial moat is therefore strongest where the excipient is embedded in a difficult-to-reproduce delivery system.

What generic entry risks exist for OSA-containing drug products?

Generic entry risk is moderate at the excipient level and potentially high at the product level.

A generic manufacturer may challenge an OSA-containing product through:

• A Paragraph IV certification against formulation or method-of-use patents
• A non-infringing formulation using another OSA-modified starch
• A different degree of substitution
• A different spray-drying process
• A 505(b)(2) application for a reformulated product
• A conventional abbreviated new drug application where equivalence is achievable

The principal barrier is proving pharmaceutical equivalence and bioequivalence. OSA-modified starch can affect dissolution, particle size, dispersion, and absorption. A substitute excipient may be legally available but technically difficult to qualify.

What licensing deals and commercial partnerships matter?

Public licensing transactions dedicated solely to octenylsuccinic acid are limited. The more common commercial arrangements involve:

• Long-term excipient supply agreements
• Private-label manufacturing
• Co-development of spray-dried formulations
• Encapsulation technology partnerships
• Distribution agreements
• Technology licensing for drug delivery platforms

Supplier contracts can include minimum purchase commitments, territorial rights, change-control obligations, audit rights, and restrictions on use in competing formulations. These agreements may materially affect customer switching costs without appearing in public patent databases.

For investors and business-development teams, a supplier’s customer concentration and qualification pipeline are more important than a simple count of OSA-related patents.

How strong is the pharmaceutical patent estate for OSA?

The standalone patent estate is weak as a broad exclusivity platform because the underlying chemical concept is mature. The application-level estate can be strong when claims cover a specific drug, dosage form, particle architecture, or manufacturing sequence.

IP layer	Relative strength
Basic OSA chemical composition	Low
OSA-modified starch composition	Moderate, depending on claim scope and prior art
Manufacturing process	Moderate to strong
Specific drug formulation	Moderate to strong
Platform delivery concept	Variable
Supplier know-how	Potentially strong but difficult to assess publicly
Orange Book protection for excipient alone	None

The strongest commercial protection is usually a combination of formulation patents, regulatory data, process know-how, and supplier qualification.

What is the likely financial outlook through the next development cycle?

The base case is gradual growth rather than explosive expansion.

Scenario	Demand pattern	Financial effect
Base case	Continued use in food and nutrition, selective pharmaceutical adoption	Stable growth with moderate pricing power
Upside case	Multiple approved oral delivery products using OSA systems	Higher pharmaceutical-grade volumes and better mix
Downside case	Formulation substitution, weak pipeline conversion, raw-material inflation	Margin pressure and limited volume growth

Revenue quality improves when suppliers move from bulk modified starch toward documented pharmaceutical grades, technical service, and co-development. The value capture is highest when the supplier participates early in formulation development and remains locked in through commercial manufacturing.

The market remains vulnerable to substitution by maltodextrin, gum arabic, cellulose polymers, synthetic surfactants, and other spray-drying carriers. OSA demand will therefore track technical performance and regulatory convenience rather than price alone.

Key Takeaways

• Pharmaceutical demand centers on OSA-modified starch, not free octenylsuccinic acid.
• The largest end markets are food, beverage, nutrition, and encapsulation; pharmaceutical use is smaller and more specialized.
• Core applications include oral emulsions, spray-dried powders, taste masking, and poorly soluble drug delivery.
• Ingredion, Tate & Lyle, Roquette, Agrana, Cargill, and specialty distributors participate in adjacent supply markets.
• No standalone FDA Orange Book exclusivity applies to OSA as an excipient.
• Patent strength is concentrated in formulation, process, and delivery-system claims.
• Public financial disclosures do not isolate OSA pharmaceutical revenue.
• The strongest commercial outlook is for documented pharmaceutical grades and co-developed delivery systems.
• Generic risk is product-specific. Suppliers benefit from qualification costs and formulation dependence rather than broad chemical exclusivity.

FAQs

Is octenylsuccinic acid the same as sodium starch octenyl succinate?

No. Octenylsuccinic acid or its anhydride is the chemical modifier. Sodium starch octenyl succinate is a starch-derived excipient made by reacting starch with an OSA reagent and neutralizing the product.

Is sodium starch octenyl succinate listed in the FDA Inactive Ingredient Database?

The FDA Inactive Ingredient Database is route-, dosage-form-, and amount-specific. A sponsor must verify the relevant entry and establish suitability for the proposed product rather than rely on the excipient name alone (U.S. Food and Drug Administration, n.d.-a).

Can OSA-modified starch be used in injectable drugs?

Its principal commercial use is oral and nonparenteral delivery. Injectable use would require separate safety, impurity, sterility, endotoxin, compatibility, and regulatory justification and should not be inferred from oral or food-use history.

Does OSA-modified starch improve drug solubility?

It can improve apparent dispersibility and assist the delivery of poorly water-soluble compounds, especially in emulsions and spray-dried systems. It does not universally increase intrinsic solubility, and performance depends on the active ingredient and formulation process.

What is the main investment risk in the OSA excipient market?

The main risk is limited pharmaceutical scale. A supplier may have technically attractive products but insufficient drug-product adoption to offset qualification costs. Substitution by established polymers and surfactants is the principal competitive risk.

References

European Commission. (n.d.). Food additives database: E1450 sodium starch octenyl succinate. European Commission.

U.S. Food and Drug Administration. (n.d.-a). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

U.S. Food and Drug Administration. (n.d.-c). 21 C.F.R. § 172.892: Food starch-modified. Electronic Code of Federal Regulations. https://www.ecfr.gov/current/title-21/section-172.892

Joint FAO/WHO Expert Committee on Food Additives. (n.d.). Compendium of food additive specifications: Modified starches. Food and Agriculture Organization of the United Nations.